The Belgium-based cell therapy group Promethera Biosciences SA/NV has confirmed John Tchelingerian as its chief executive officer to lead development of new cell-based treatments for liver disease. Dr Tchelingerian has been the company’s interim CEO since January 2015. As both an entrepreneur and private investor, Dr Tchelingerian has pioneered the use of cell therapy for the treatment of central nervous system disorders, as well as co-founded the corporate finance firm Silver Ocean Venture. He holds a PhD in neurosciences firm the Pierre et Marie Curie University in Paris.
Promethera announced the appointment on 23 September 2015.
Copyright 2015 Evernow Publishing Ltd